An Australian stem cell and regenerative medicine company

FAQ: Cynata Partner apceth GmbH & Co Completes Cymerus™ Evaluation

Cynata’s technology was recently investigated by German Company apceth GmbH & Co. KG, what did this result in?

Cynata’s Cymerus™ mesenchymal stem cell (MSC) technology was assessed in apceth’s in-house cell culture and genetic modification systems. The outcome was considered by both parties to be very successful. The activity was undertaken as part of the option agreement between the two parties and was designed to evaluate the applicability of Cynata’s MSCs in apceth’s unique approach to engineering new properties into MSCs, not only for use in treating cancer but also in treating a number of other devastating diseases. apceth’s evaluation demonstrated not only the success of the Cymerus™ platform but its ability to successfully integrate with other technologies.

What are the next steps with apceth GmbH & Co. KG?

The collaboration between apceth and Cynata continues. The successful evaluation of Cynata’s Cymerus™ technology by apceth opens up new opportunities for Cynata both with apceth and with other biopharmaceutical companies in treating a number of devastating diseases, including cancer. This follows a decision by apceth to review its internal strategy to no longer pursue cancer treatments, opening the field of oncology for discussions with other biopharmaceutical companies. Whilst the disease focus of the collaboration has now changed, the business relationship continues and apceth is keen to collaborate with Cynata in other areas of research, given the positive outcomes from their evaluation of Cymerus™. These new opportunities for engineered MSCs are in addition to the existing partnership with FUJIFILM to develop and commercialise CymerusTM MSCs in the prevention and treatment for Graft v Host Disease (GvHD).

Will Cynata continue research in cancer?

Cynata is undertaking a research program in genetically modified MSCs in cancer through a collaboration with Massachusetts General Hospital, the largest teaching hospital of Harvard Medical School. The apceth evaluation has been very helpful in providing additional confirmatory data that Cynata’s Cymerus technology is very appropriate for use in genetic modification to enhance cancer-killing properties of the cells. Find out more here:

What else is Cynata working on?

Cynata has proved that the Cymerus technology is effective in various animal models of specific diseases. In a world-first, Cynata is undertaking a clinical trial of CYP-001, a patented Cymerus product for graft-versus-host disease (GvHD). If the technology is effective in these clinical trials, it will fast track commercialization of the platform technology for further diseases that represent major unmet medical needs. Here’s a snapshot of what else Cynata is working on:

Heart attacks

  • Preliminary results from pre-clinical trials suggests that Cymerus™ iPSC-generated MSCs may have the potential to restore cardiac function and reduce scar size after a heart attack. Read more here.

Graft-vs-host disease (GvHD)

  • Successfully completed pre-clinical research to show that Cymerus™ MSCs can be an effective treatment for GvHD. Results showed that CYP-001 treatment substantially prolonged survival in an animal model.
  • The upcoming clinical trial in GvHD is believed to be the first clinical trial worldwide involving an allogeneic therapeutic MSC product derived from induced pluripotent stem cells (iPSCs). Read more here.

Asthma and lung disease

  • Cymerus™ MSCs have demonstrated significant beneficial effects on three key components of asthma: airway hyper-responsiveness, inflammation and airway remodeling. Read more here.